tazarotene has been researched along with Carcinoma, Basal Cell in 13 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To review a decade of experience using tazarotene as a monotherapy or as combination therapy for approved and other indications: acne, psoriasis, photoaging, basal cell carcinomas and various keratinization disorders." | 4.85 | Efficacy and safety of topical tazarotene: a review. ( Cox, K; Duvic, M; Talpur, R, 2009) |
| "Tazarotene treatment was associated with increased TIG-3 protein and mRNA expression in basal cell carcinomas compared to baseline levels (p < or = 0." | 2.71 | Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. ( Duvic, M; Hazarika, P; Herne, K; Joseph, A; Ni, X; Schulz, C; Sui, D; Talpur, R; Ward, S, 2003) |
| "Tazarotene 0." | 2.71 | Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. ( Angeloni, C; Bianchi, L; Campione, E; Chimenti, S; Costanzo, A; Orlandi, A; Spagnoli, LG, 2004) |
| "Tazarotene was the most effective of the preparations studied, and its effect most likely was mediated by RARgamma activation." | 1.35 | Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. ( Epstein, EH; Fujimoto, MA; So, PL, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, JY | 1 |
| Chiou, AS | 1 |
| Mackay-Wiggan, JM | 1 |
| Aszterbaum, M | 2 |
| Chanana, AM | 1 |
| Lee, W | 1 |
| Lindgren, JA | 1 |
| Raphael, MA | 1 |
| Thompson, BJ | 1 |
| Bickers, DR | 1 |
| Epstein, EH | 5 |
| So, PL | 4 |
| Wang, GY | 2 |
| Wang, K | 1 |
| Chuang, M | 1 |
| Chiueh, VC | 1 |
| Kenny, PA | 1 |
| Wu, CS | 1 |
| Chen, GS | 1 |
| Lin, PY | 1 |
| Pan, IH | 1 |
| Wang, ST | 1 |
| Lin, SH | 1 |
| Yu, HS | 1 |
| Lin, CC | 1 |
| Talpur, R | 2 |
| Cox, K | 1 |
| Duvic, M | 2 |
| Brightman, L | 1 |
| Warycha, M | 1 |
| Anolik, R | 1 |
| Geronemus, R | 1 |
| Wang, L | 1 |
| Libove, E | 1 |
| Wang, J | 1 |
| Ni, X | 1 |
| Herne, K | 1 |
| Schulz, C | 1 |
| Sui, D | 1 |
| Ward, S | 1 |
| Joseph, A | 1 |
| Hazarika, P | 1 |
| Orlandi, A | 2 |
| Bianchi, L | 2 |
| Costanzo, A | 2 |
| Campione, E | 2 |
| Giusto Spagnoli, L | 1 |
| Chimenti, S | 4 |
| Lee, K | 1 |
| Hebert, J | 1 |
| Walker, P | 1 |
| Lu, Y | 1 |
| Hwang, J | 1 |
| Kopelovich, L | 1 |
| Athar, M | 1 |
| Bickers, D | 1 |
| Angeloni, C | 1 |
| Spagnoli, LG | 1 |
| Peris, K | 2 |
| Ferrari, A | 1 |
| Fargnoli, MC | 2 |
| Piccolo, D | 1 |
| Fujimoto, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome[NCT00489086] | Phase 2 | 36 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial[NCT02721173] | Phase 4 | 60 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint used to evaluate tazarotene efficacy for BCC chemotherapy was the complete response (CR) rate, defined as the complete visible disappearance of a patient's target lesion during the the 18 months of tazarotene application and its failure to recur during the ensuing 18-months. We defined surgical removal of a target lesion as a treatment failure. The primary endpoint was assessed based on intention to treat analysis such that any subject who underwent the baseline evaluation and applied at least 1 dose of tazarotene was included in the analysis. Drop-outs were considered non-responders. A priori treatment success for tazarotene was defined as a CR rate of at least 50%, and treatment failure was defined as a CR rate of 25% or less." (NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | 2 |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
2 reviews available for tazarotene and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Efficacy and safety of topical tazarotene: a review.
Topics: Acne Vulgaris; Administration, Cutaneous; Animals; Carcinoma, Basal Cell; Dermatologic Agents; Human | 2009 |
Do lasers or topicals really work for nonmelanoma skin cancers?
Topics: Administration, Cutaneous; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2011 |
5 trials available for tazarotene and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome.
Topics: Adult; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Cross-Over Studies; Dermatologic Agents; Do | 2014 |
Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application.
Topics: Administration, Topical; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Dermatologic Agents; Epider | 2003 |
Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Basal Cell; Carcin | 2004 |
Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; bcl-2-Associated X P | 2004 |
Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Dermatologic Agent | 2005 |
6 other studies available for tazarotene and Carcinoma, Basal Cell
| Article | Year |
|---|---|
PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Basal Cell; Cell Proliferation; Cell Transformatio | 2014 |
Tazarotene induces apoptosis in human basal cell carcinoma via activation of caspase-8/t-Bid and the reactive oxygen species-dependent mitochondrial pathway.
Topics: Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Basal Cell; Caspa | 2014 |
Establishment of murine basal cell carcinoma allografts: a potential model for preclinical drug testing and for molecular analysis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Basal Cell; Disease Models, Animal; Female; Hedgehog Prot | 2011 |
Topical tazarotene chemoprevention reduces Basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation.
Topics: Administration, Topical; Animals; Anticarcinogenic Agents; Carcinoma, Basal Cell; Female; Genetic Pr | 2004 |
Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis.
Topics: Animals; Anticarcinogenic Agents; Carcinoma, Basal Cell; Hedgehog Proteins; Keratinocytes; Mice; Mic | 2008 |
Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Female; Gels; Huma | 1999 |